Giulio Draetta

Giulio Draetta

UNVERIFIED PROFILE

Are you Giulio Draetta?   Register this Author

Register author
Giulio Draetta

Giulio Draetta

Publications by authors named "Giulio Draetta"

Are you Giulio Draetta?   Register this Author

49Publications

-Reads

Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription.

Cancer Discov 2018 Jan;8(1):17-19

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
January 2018

Metabolic Features of Cancer Treatment Resistance.

Recent Results Cancer Res 2016;207:135-56

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article
March 2017

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Cell 2017 02;168(4):579-583

Division of Molecular Carcinogenesis and Cancer Genomics Centre Netherlands, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address:

View Article
February 2017

Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair.

Cell Rep 2016 Feb 4;14(6):1555-1566. Epub 2016 Feb 4.

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article
February 2016

Genetics and biology of pancreatic ductal adenocarcinoma.

Genes Dev 2016 Feb;30(4):355-85

Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA;

View Article
February 2016

Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells.

Cell Metab 2015 Oct;22(4):543-5

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
October 2015

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

Cancer Res 2015 Mar 3;75(6):1091-101. Epub 2015 Mar 3.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
March 2015

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Nature 2014 Oct 10;514(7524):628-32. Epub 2014 Aug 10.

1] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
October 2014

Oncology drug discovery: planning a turnaround.

Cancer Discov 2014 Apr;4(4):397-404

1Institute for Applied Cancer Science, Departments of 2Genomic Medicine and 3Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 4On-kos, Milan, Italy.

View Article
April 2014

Cancer drug discovery faces the FACT.

Sci Transl Med 2011 Aug;3(95):95ps34

Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article
August 2011

Role for histone deacetylase 1 in human tumor cell proliferation.

Mol Cell Biol 2007 Jul 30;27(13):4784-95. Epub 2007 Apr 30.

European Institute of Oncology, Department of Experimental Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article
July 2007

SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins.

Science 2007 May 26;316(5826):900-4. Epub 2007 Apr 26.

Department of Pathology, NYU Cancer Institute, New York University School of Medicine, 550 First Avenue, MSB 599, New York, NY 10016, USA.

View Article
May 2007

Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation.

Biochem Biophys Res Commun 2006 Jun 19;344(3):859-68. Epub 2006 Apr 19.

European Institute of Oncology, 435 Via Ripamonti, 20141 Milan, Italy.

View Article
June 2006

Commentary on "A new cancer diagnostic system based on a CDK profiling technology" [Biochim. Biophys. Acta Molecular Basis of Disease 1741 (2005) 226-233].

Authors:
Giulio F Draetta

Biochim Biophys Acta 2005 Sep;1741(3):225

Cancer Research, Merck Research Laboratories, Basic Research, 33 Avenue Louis Pasteur, Boston, MA 02115, USA.

View Article
September 2005

Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Mol Cell Biol 2005 Apr;25(8):3338-47

Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, Chicago, IL 60607, USA.

View Article
April 2005

A mechanism for inhibiting the SUMO pathway.

Mol Cell 2004 Nov;16(4):549-61

European Institute of Oncology, Department of Experimental Oncology, 20141 Milan, Italy.

View Article
November 2004

Characterization of the BUD31 gene of Saccharomyces cerevisiae.

Biochem Biophys Res Commun 2004 Aug;320(4):1342-50

Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.

View Article
August 2004

Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis.

Oncogene 2004 Mar;23(11):2050-6

European Institute of Oncology, 435 Via Ripamonti, Milan 20141, Italy.

View Article
March 2004

Regulating mammalian checkpoints through Cdc25 inactivation.

EMBO Rep 2003 Jul;4(7):671-7

European Institute of Oncology, 435 Via Ripamonti, 20141 Milan, Italy.

View Article
July 2003

Modulation of p120E4F transcriptional activity by the Gam1 adenoviral early protein.

Oncogene 2003 May;22(17):2541-7

Department of Experimental Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy.

View Article
May 2003

The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1.

EMBO Rep 2002 Nov 22;3(11):1062-8. Epub 2002 Oct 22.

European Institute of Oncology, Department of Experimental Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article
November 2002

Dual mode of degradation of Cdc25 A phosphatase.

EMBO J 2002 Sep;21(18):4875-84

European Institute of Oncology, 435 Via Ripamonti, I-20141 Milan, Italy.

View Article
September 2002

Histone deacetylase 1 inactivation by an adenovirus early gene product.

Curr Biol 2002 Apr;12(7):594-8

Department of Experimental Oncology, European Institute of Oncology, 20141, Milan, Italy.

View Article
April 2002